Text Request Honored with Inc. Power Partner Award for 2nd Year
October 24, 2023 07:33 ET
|
Text Request
CHATTANOOGA, TENN., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Text Request, the industry-leading business messaging platform, has been recognized as an Inc. Power Partner for the second year in a row....
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
October 03, 2023 07:00 ET
|
Aclaris Therapeutics, Inc.
- Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 20, 2023 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
September 18, 2023 07:00 ET
|
Aclaris Therapeutics, Inc.
– Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases – WAYNE, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc....
Psoriatic Arthritis Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - Bristol-Myers Squibb, Aclaris, AbbVie, Novartis, Janssen, MoonLake, Affibody, Amgen, Eli Lilly
August 31, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Psoriatic Arthritis Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - Bristol-Myers Squibb, Aclaris,...
Barrack, Rodos & Bacine Investigates Napco Security Technologies, Inc. (NSSC)
August 24, 2023 09:30 ET
|
Barrack Rodos & Bacine
PHILADELPHIA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine (BR&B) is investigating Napco Security Technologies, Inc. (“Napco”) (NASDAQ: NSSC) for potential violations of federal...
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 07, 2023 07:00 ET
|
Aclaris Therapeutics, Inc.
- Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023 - WAYNE, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aclaris...
Psoriasis Market to Register Immense Growth by 2032, Predicts DelveInsight | Key Companies Working in Space - Biohaven, Bristol-Myers Squibb, UCB Pharma, Janssen, Novartis, Pfizer, Boehringer Ingelheim, AbbVie, Aclaris
July 25, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 25, 2023 (GLOBE NEWSWIRE) -- Psoriasis Market to Register Immense Growth by 2032, Predicts DelveInsight | Key Companies Working in Space - Biohaven, Bristol-Myers Squibb, UCB...
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)
June 13, 2023 07:01 ET
|
Aclaris Therapeutics, Inc.
- Topline Data Anticipated in Q4 2023 WAYNE, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
June 02, 2023 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...